Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.42 |
| ▸ | GNRHR | P30968 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985729 | 0.89 | TBK1 (0.44) | AURKAGNRHR | |
| SCHEMBL211207 | 0.89 | AURKA (0.53) | AURKAGNRHRIGF1RCYP1A2CYP2D6 | |
| SCHEMBL13985706 | 0.87 | AURKA (0.44) | AURKAGNRHRKCNH2 | |
| SCHEMBL13985592 | 0.86 | TBK1 (0.42) | AURKAGNRHRIGF1RROCK2 | |
| SCHEMBL13985737 | 0.84 | AURKA (0.55) | AURKAKCNH2 | |
| SCHEMBL210188 | 0.83 | AURKA (0.48) | AURKAGNRHRIGF1RROCK2KIT | |
| SCHEMBL13985464 | 0.83 | AURKA (0.50) | AURKAGNRHRCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4754714 | 0.82 | AURKA (0.52) | AURKACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13985645 | 0.81 | AURKA (0.51) | AURKACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13985468 | 0.79 | AURKA (0.41) | AURKAIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |